This report is of great interest to our Firm, as we are currently investigating legal claims on behalf of women who are now tragically facing advanced stage uterine cancers that were allegedly spread by morcellation.
New York, New York (PRWEB) June 20, 2014
As the Firm continues to investigate power morcellator lawsuits (http://www.morcellatorlawsuit2015.com/) , Bernstein Liebhard LLP notes the publication of a new report detailing a containment bag technique that could mitigate the cancer risks associated with uterine morcellation. The report, which appeared in OB. GYN. News on June 16th, acknowledges that many doctors have found such bags too difficult to use with power morcellators. But the authors of the article maintain that their technique, for which they provide step-by-step instructions, will give surgeons room to maneuver and improve their ability to see what they are doing. The report also noted that one of its co-authors is working to develop a morcellator that already includes a containment bag that will open automatically to help in catching morcellated tissue.*
“This report is of great interest to our Firm, as we are currently investigating legal claims on behalf of women who are now tragically facing advanced stage uterine cancers that were allegedly spread by morcellation,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now offering free morcellator lawsuit reviews to women who may have experienced the spread of undiagnosed uterine sarcoma and other cancers due to uterine morcellation.
Morcellator Cancer Risks
Power morcellators are used in minimally-invasive gynecological surgeries to cut up tissue so that it can be removed through the abdomen via a small incision. In April, the U.S. Food & Drug Administration (FDA) issued an alert discouraging doctors from using power morcellators in laparoscopic hysterectomies and fibroid removal procedures, after the agency’s review found that the devices could promote the dissemination of undetected cancer cells from the uterus to the peritoneal cavity.
Among other things, the FDA said that roughly 1 in 350 women in need of fibroid removal actually has undiagnosed uterine sarcoma. The spread of the cancer outside of the uterus results in an upstaging of the disease, and greatly diminishes a woman’s chances of long-term survival. The FDA is scheduled to convene a meeting of its Obstetrics and Gynecological Devices Panel starting on July 10th to further investigate the use of power morcellators in uterine surgery, and make recommendation for mitigating their risks.
Since the FDA alert was issued in April, Johnson & Johnson announced it would suspend sales of several power morcellators sold by its Ethicon, Inc. unit until the agency can provide further guidance on their use.** A number of hospitals, including Brigham and Women's Hospital in Boston have stopped using the devices pending action from the FDA.***
According to court documents, a number of power morcellator lawsuits are now pending in U.S. courts, all of which were brought on behalf of women whose cancer was allegedly spread via uterine morcellation. Most recently, a case was filed in the U.S. District Court, Northern District of California on May 13, 2014 that claims the use of a Wolf Power Morcellator promoted the seeding of uterine cancer cells throughout a woman's peritoneal cavity. (Case No. Case5:14-cv-02209-PSG)
Alleged victims of uterine sarcoma or other cancers spread via power morcellation may be entitled to compensation for their injury-related damages. To learn more about filing a morcellator lawsuit, please visit Bernstein Liebhard LLP's website. To obtain a free legal review, please call 800-511-5092.
*obgynnews.com/home/article/safety-techniques-regarding-morcellation/33cebea3325dae2bbee708d50bef8594.html?tx_ttnews[sViewPointer]=1, OB. GYN. News, June 16, 2014
**reuters.com/article/2014/04/30/us-johnson-johnson-device-idUSKBN0DG06G20140430, Reuters, April 30, 2014
***cleveland.com/healthfit/index.ssf/2014/04/surgical_tool_for_hysterectomy.html, Cleveland Plain Dealer, April 28, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York States contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firms fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiffs’ recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP